EP0822758A1 - Supplement for baby infant formula and a method of delivering that supplement - Google Patents
Supplement for baby infant formula and a method of delivering that supplementInfo
- Publication number
- EP0822758A1 EP0822758A1 EP96902819A EP96902819A EP0822758A1 EP 0822758 A1 EP0822758 A1 EP 0822758A1 EP 96902819 A EP96902819 A EP 96902819A EP 96902819 A EP96902819 A EP 96902819A EP 0822758 A1 EP0822758 A1 EP 0822758A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- supplement
- oil
- acid
- fatty acids
- supplement according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/04—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing non-milk fats but no non-milk proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- the present invention relates to a supplement for baby infant formula and a method of delivering that supplement.
- the invention relates to a stable delivery system of a supplement of long chain polyunsaturated fatty acids docosahexaenoic acid 22:6 ⁇ 3 (DHA), eicosapentaenoic acid 20:5 ⁇ 3 (EPA), gamma linolenic acid 18:3 ⁇ 6 (GLA) and arachidonic acid 20:4 ⁇ 6 (AA) from tuna oil in combination with evening primrose oil to infant milk formula so that the formula approximates breast milk.
- DHA long chain polyunsaturated fatty acids
- EPA eicosapentaenoic acid 20:5 ⁇ 3
- GLA gamma linolenic acid 18:3 ⁇ 6
- AA arachidonic acid
- the invention also relates to a method of treatment using the supplement of this invention.
- DHA docosahexaenoic acid
- AA arachidonic acid
- DHA and AA by altering the vegetable oil content of infant formula.
- DHA and AA are required to be present in the formula along with an oil containing GLA.
- compositions of fish oil have high EPA and DHA with a total Omega-3 of
- a supplement for addition to an infant milk formula comprising a blend of essential fatty acids at a level sufficient to approximate the level found in natural breast milk.
- the supplement is effective in increasing DHA in infants being fed the formula and/or is effective in maintaining high levels of AA in these infants and/or is effective in increasing GLA in these infants.
- a supplement for addition to an infant milk formula comprising a blend of essential fatty acids at a level sufficient to approximate the level found in natural breast milk encapsulated in a suitable material.
- the capsule is soft gelatin and is provided with a teat which for example is able to be snipped, thereby allowing the contents of the capsule to be discharged into standard milk formulation whenever required.
- a teat which for example is able to be snipped, thereby allowing the contents of the capsule to be discharged into standard milk formulation whenever required.
- a method for improving the visual evoked response in infants comprises administering to said infants an effective amount of a supplement for addition to an infant milk formula comprising a blend of essential fatty acids at a level sufficient to approximate the level found in natural breast milk.
- the DHA, EPA and AA are extracted from phytoplankton, zooplankton, bacterial polyunsaturated fatty acid producers, and fish.
- the blend preferably is prepared from oil extracted from fish and is more preferably extracted from tuna fish and mullet ie. fish of the Scombridae and Mugilidae families. Species of tuna fish which are suitable are albacore, bluefin, yellowfin and western pacific skipjack. Tuna oil has a preferred ratio of DHA:EPA. Although tuna oil is preferably used as a source of DHA, EPA, and AA, any fish which provides suitable levels of these long chain unstable fatty acids will suffice. A further source of preferred blends of fatty acids may be extracted from algae.
- the fish oil preferably contains high levels of DHA of between about 25-30% of total fat and a DHA:EPA ratio of about 4.0-7.0: 1 and AA of about 1.7-2.5 % of total fat together with a evening primrose oil in a blend of about 80% fish oil to about 20% evening primrose oil.
- the evening primrose oil contains a GLA of 10% or more.
- the blend also preferably contains evening primrose oil. This is suitably prepared by cold pressing and filtering or from solvent extracts containing essential fatty acids or their metabolites or using supercritical extraction techniques. Suitable solvents when using the solvent extraction method are for example hexane or isopropanol.
- the blend also suitably contains an emulsifer or blends of emulsifiers. For example, a typical emulsifier is lecithin.
- the blend may also contain antioxidants such as mixed natural tocopherols. If desired, the blend may also contain trace elements such as selenium; coenzymes such as coenzyme Q10; minerals such as calcium; other essential fatty acids; and other herbal extracts.
- antioxidants such as mixed natural tocopherols.
- trace elements such as selenium; coenzymes such as coenzyme Q10; minerals such as calcium; other essential fatty acids; and other herbal extracts.
- the blend may also contain vitamins.
- vitamins it may be desirable to add vitamins in geographical areas where such a vitamin is below recommended levels or deficient.
- fat soluble vitamins such as vitamin E may be added.
- the oils are passed by quality assurance as meeting the specifications for raw material as defined.
- the mixing vessel is capped under food grade nitrogen nad taken to the encapsulation room.
- the blended oil is then encapsulated into 500gm soft gelatine capsules.
- Example 1 Production and Processing of Tuna Oil (fish oil)
- the raw material for the production of fish or tuna oil fall into two classes.
- the first category of raw materials is the pelagic-type fish specifically pursued for reduction to meal and oil.
- the second category is from facilities that produce edible fish such as salmon or tuna.
- the universal process used to produce fish or tuna oil is the wet rendering process. Major steps in the process are cooking, pressing, drying and separating.
- Cooking coagulates the fish protein so that the liquid and solids can be mechanically separated.
- the oil is then separated from the pressliquid by centrifugation.
- the crude tuna oil contains impurities which reduce the acceptability because of the flavours and odours and also reduce the stability and shelf life of the oil.
- To produce a safe, edible product the crude oil has to undergo certain processing steps which include degumming, neutralisation, bleaching, winterisation and deodorisation.
- the degumming step removes hydrated gums, phosphorous and trace metals.
- the subsequent alkali treatment neutralises the free fatty acids and removes the hydrated gums with the soapstock.
- Bleaching is used to improve the colour, flavour and oxidative stability of the oil and also impurities, such as traces of soap.
- the seed is mechanically pressed using a screw press at a maximum temperature of about 50°C.
- the crude oil contains impurities which reduce the consumer acceptability because of flavours and odours and can reduce the shelf life of the oil.
- To produce a safe, edible oil product the oil has to undergo certain processing steps which include degumming, neutralisation, bleaching, winterisation and deodorisation.
- the degumming step removes hydrated gums, phosphorous and trace metals.
- the subsequent alkali treatment neutralises the free fatty acids and removes the hydrated gums with the soapstock.
- Bleaching is used to improve the colour, flavour and oxidative stability of the oil and also impurities, such as traces of soap.
- the evening primrose seeds are rolled, or "prepressed", to crack the seed producing a cake, with final extraction of the oil achieved by solvent extraction.
- the solvent usually hexane, leaches the oil out of the cake.
- the leached oil and solvent form a mixture which is referred to as "Miscella”. It is essential to have enough clean solvent to keep miscella low enough in concentration to dissolve and displace more oil at each stage of extraction.
- the process occurs under gentle stirring, in an extractor, to ensure good contact and penetration, such that solvent contacts oil and is able to flow out of the particles with the oil.
- the miscella from the extractor contains about 22-30% oil and the rest is solvent.
- the basic process is to heat this mixture under a vacuum and evaporate out the solvent, leaving the oil behind.
- the oil is then steam stripped in a counterflow process and goes into storage as crude oil.
- the solvent vapours are condensed, separated from water, heated and sent back to the extractor. This procedure may be repeated to reduce the solvent content in the oil to below 1 ppm or lower. Residual solvent is extracted at a maximum temperature of about 50 to about 60°C.
- the crude oil is then refined in the same manner as evening primrose oil detailed in (i) above.
- Example 3 Blending of Oils Tuna oil and Evening Primrose oil were mixed together at precise ratios (w/w) under nitrogen.
- Example 4 Measurement of Visual Evoked Response in Infants Visual evoked response, expressed as visual evoked potential or VEP. is measured according to Sokol, S. Vision Research 18, 33-39 as follows. Infants sat with their mothers 1 metre away from a monitor that presented high-contrast black-and-white checkerboard-pattern stimuli. A constant reversal rate of 2/s was used to elicit responses to checks with squares subtending visual angles of 7, 17, 34, 69 and 137 min of arc.
- Peak-to-peak amplitude was determined for each check size. The amplitude of the evoked potential diminishes as check size decreases. Extrapolation of a regression line fitting VEP amplitude to log (check size) through 0- ⁇ V amplitude gives the smallest check size that, if tested, would render a positive wave. This point is defined as the logMAR or VEP acuity.
- Blood samples 150 to 200 u ⁇ whole blood was obtained from a heel prick and transferred to tubes containing ethylenediamine tetracetic acid. After removal of plasma, erythrocytes were washed three times with cold isotonic saline solution and the lipids were extracted immediately.
- Lipid extraction Total lipids were extracted from plasma and infant formula with chloroform/methanol (2: 1 vol/vol) and from erythrocyte membranes with chloroform isopropanol (2: 1 vol/vol).
- Fatty Acid methylation Plasma, erythrocyte, and infant formula lipid extracts were evaporated to dryness under nitrogen.
- the samples were methylated in 1 % H 2 SO 4 in methanol at 70°C for 3 hours. After cooling, the resulting methyl esters were extracted into n-heptane and transferred to vials containing anhydrous Na 2 SO 4 as the dehydrating agent.
- Tetracosaenoic 24 l ⁇ 9 -
- the acid value was determined using method Cd 3d-63 of the American Oil Chemists Society.
- the peroxide value was determined using method Cd 8b-90 of the American Oil Chemists Society.
- the anisidine value was determined using method BS684 2.24: 1989.
- Example 9 The following table sets out an example of the contents of a typical capsule according to this invention together with the constitution of the shell of such a capsule.
- Example 1 As a general rule, one drop of the supplement, an instance of which appears in Example 9, is added to 30mL of milk formula.
- Example 1 1
- Salmonella/ lOg ND Salmonella/ lOg ND
- Salmonella/ lOg ND Salmonella/ lOg ND
- Salmonella/ lOg ND Salmonella/ lOg ND
- Salmonella/ lOg ND Salmonella/ lOg ND
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPN1378A AUPN137895A0 (en) | 1995-02-27 | 1995-02-27 | Composition and method |
AUPN1378/95 | 1995-02-27 | ||
PCT/AU1996/000103 WO1996026647A1 (en) | 1995-02-27 | 1996-02-27 | Supplement for baby infant formula and a method of delivering that supplement |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0822758A1 true EP0822758A1 (en) | 1998-02-11 |
EP0822758A4 EP0822758A4 (en) | 1998-07-01 |
Family
ID=3785735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96902819A Withdrawn EP0822758A4 (en) | 1995-02-27 | 1996-02-27 | Supplement for baby infant formula and a method of delivering that supplement |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0822758A4 (en) |
JP (1) | JPH11500909A (en) |
KR (1) | KR19980702672A (en) |
AU (1) | AUPN137895A0 (en) |
BR (1) | BR9607455A (en) |
CA (1) | CA2213971A1 (en) |
WO (1) | WO1996026647A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071963A (en) * | 1996-11-06 | 2000-06-06 | Roche Vitamins Inc. | Water dispersible compositions |
KR100488512B1 (en) * | 2002-05-09 | 2005-05-11 | 에스티케이제약 주식회사 | healthy foodstuffs mainly including seed oil of evening primrose and the composion thereof |
SI2672837T2 (en) * | 2011-02-11 | 2022-11-30 | Clover Corporation Limited | Nutritional compositions and uses thereof |
US9561206B2 (en) * | 2015-01-07 | 2017-02-07 | The United States Of America, As Represented By The Secretary Of The Navy | Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome |
US10966937B2 (en) * | 2015-05-04 | 2021-04-06 | Cytometix, Inc. | Compositions and methods for delivery of polyunsaturated fatty acid derivatives and analogs |
JP7169264B2 (en) * | 2016-04-14 | 2022-11-10 | クローバー・コーポレイション・リミテッド | Methods of manufacturing nutritional formulations |
EP4257187A3 (en) | 2017-05-23 | 2023-11-22 | Nissui Corporation | Composition for improving vascular endothelial function |
WO2019083816A1 (en) | 2017-10-23 | 2019-05-02 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670285A (en) * | 1982-08-06 | 1987-06-02 | The University Of Toronto Innovations Foundation | Infant formula |
DK0568606T3 (en) * | 1991-01-24 | 2001-07-23 | Martek Corp | Microbial oil mixtures and applications thereof |
DK88692D0 (en) * | 1992-07-06 | 1992-07-06 | Danochemo As | PROCEDURE FOR MANUFACTURING MICROCAPPLES |
-
1995
- 1995-02-27 AU AUPN1378A patent/AUPN137895A0/en not_active Abandoned
-
1996
- 1996-02-27 BR BR9607455A patent/BR9607455A/en not_active Application Discontinuation
- 1996-02-27 KR KR1019970706078A patent/KR19980702672A/en not_active Application Discontinuation
- 1996-02-27 EP EP96902819A patent/EP0822758A4/en not_active Withdrawn
- 1996-02-27 WO PCT/AU1996/000103 patent/WO1996026647A1/en not_active Application Discontinuation
- 1996-02-27 CA CA002213971A patent/CA2213971A1/en not_active Abandoned
- 1996-02-27 JP JP8525906A patent/JPH11500909A/en active Pending
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO9626647A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2213971A1 (en) | 1996-09-06 |
KR19980702672A (en) | 1998-08-05 |
WO1996026647A1 (en) | 1996-09-06 |
BR9607455A (en) | 1998-06-30 |
EP0822758A4 (en) | 1998-07-01 |
AUPN137895A0 (en) | 1995-03-16 |
JPH11500909A (en) | 1999-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8173160B2 (en) | Compositions comprising edible oils and vitamins and/or minerals and methods for making the compositions | |
AU716372B2 (en) | Food composition containing an omega-6/omega-3 unsaturated fatty acid balance modifier | |
ES2300115T3 (en) | EDIBLE FATS CONTAINING ARACHIDONIC ACID AND FOODS CONTAINING THE SAME. | |
RU2288255C2 (en) | Oil containing one or some long-chain polyunsaturated fatty acids prepared from biomass, method for its preparing, children mixture, nutritive or fodder foodstuff or nutrient, cosmetic or pharmaceutical composition comprising thereof | |
CS277394B6 (en) | Process for preparing refined oil | |
JP2002540221A5 (en) | ||
TW201306752A (en) | Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child | |
US7776375B2 (en) | Process for preparing an oil containing one or more long-chain polyunsaturated fatty acids derived from biomass; foodstuff or nutritional, cosmetic or pharmaceutical composition containing it | |
AU2002257609A1 (en) | Oil containing one or more long-chain polyunsaturated fatty acids derived from biomass, process for preparing it, foodstuff, or nutritional, cosmetic or pharmaceutical composition containing it | |
CN107441217B (en) | Oral emulsion rich in alpha-linolenic acid and preparation method thereof | |
EP0822758A1 (en) | Supplement for baby infant formula and a method of delivering that supplement | |
JP2024023267A (en) | Polyunsaturated fatty acid composition rich in DHA | |
US10993456B2 (en) | Oil blends, processes for the preparation thereof and their use in formulas | |
AU706613B2 (en) | Supplement for baby infant formula and a method of delivering that supplement | |
JP5269373B2 (en) | Liquid composition for soft capsule filling | |
KR20190040141A (en) | Oil blends and process for their preparation | |
Dalvi‐Isfahan et al. | Ostrich oil as a fat substitute in milk‐based infant formula | |
TW384209B (en) | A supplement for addition to an infant milk formula | |
CA3000103C (en) | Process for the preparation and stabilization of emulsions with omega-3 by means of isometric crystalline networks of cellulose derivatives | |
US3325291A (en) | Process for the preparation of solutions of phosphatides in edible oils | |
Karimi Dehcheshmeh et al. | Effect of Heat Drying Process on Fatty Acid Structure of Vegetable Oil in Infant Formula | |
Fé | Changes in some components of the unsaponifiable fraction of coconut oil during refining | |
WO2017063746A1 (en) | Capsules for lowering serum cholesterol | |
Kawekwune et al. | Comparative Study of the Physicochemical Properties and Fatty Acid Profile of Oil Extracted from Flesh and Viscera of Farmed Catfish (Clarias gariepinus) at Three Different Ages | |
TW201233329A (en) | Nutritional products including a novel fat system including monoglycerides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970930 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19980518 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20010507 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20011120 |